Literature DB >> 33340067

[Imaging: The oncologist's perspective].

S Fuxius1.   

Abstract

CLINICAL ISSUE: Modern oncology has implemented several novel modalities, which increasingly warrant interdisciplinarity, dedicated imaging methods as well as intensive communication between imager and oncologists. STANDARD TREATMENT: The classical pillars of cancer treatment are surgery, radiotherapy, and chemotherapy. TREATMENT INNOVATIONS: Evidence-based oncology, radio-oncology, and surgery, individualized precision oncology, novel drug classes, immuno-oncology, minimally invasive diagnostic and treatment methods. DIAGNOSTIC WORK-UP: Standard imaging methods are undergoing constant innovation and are being supplemented by specific radiotracers that can be used for radionuclide therapy. Adapted response criteria are to be used in the context of targeted therapy or checkpoint inhibitors. PERFORMANCE AND ACHIEVEMENT: Modern cancer treatment enables improved tumor control. Due to its complexity, however, it increasingly warrants structured reporting and intense communication between imager and oncologists, to make best use of its potential.

Entities:  

Keywords:  Cancer diagnostics; Immune therapy; Precision oncology; Radiation oncology; Targeted therapy

Mesh:

Year:  2020        PMID: 33340067     DOI: 10.1007/s00117-020-00790-3

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  4 in total

Review 1.  The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches.

Authors:  Mirjam Gerwing; Ken Herrmann; Anne Helfen; Christoph Schliemann; Wolfgang E Berdel; Michel Eisenblätter; Moritz Wildgruber
Journal:  Nat Rev Clin Oncol       Date:  2019-07       Impact factor: 66.675

Review 2.  Optimizing the treatment of liver metastases from uveal melanomas with transarterial chemoembolization using melphalan and calibrated microspheres.

Authors:  Xavier Carle; Lauris Gastaud; Julia Salleron; Magali Pascale Tardy; Jean-Pierre Caujolle; Antoine Thyss; Juliette Thariat; Patrick Chevallier
Journal:  Bull Cancer       Date:  2020-11-09       Impact factor: 1.276

3.  PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.

Authors:  Joachim Drevs; Ralph Müller-Driver; Christine Wittig; Stefan Fuxius; Norbert Esser; Harald Hugenschmidt; Moritz A Konerding; Peter R Allegrini; Jeanette Wood; Jürgen Hennig; Clemens Unger; Dieter Marmé
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

Review 4.  [Therapy of locally recurrent rectal carcinoma].

Authors:  H G Hempen; H R Raab
Journal:  Chirurg       Date:  2009-04       Impact factor: 0.955

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.